Fuller & Thaler Asset Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-985,660	Closed	-$1.81M	–	547
2023 Q2	$1.81M	Buy	985,660 +3,125	+0.3%	+$7.23K	0.01%	366
2023 Q1	$2.39M	Sell	982,535 -750	-0.1%	-$1.11K	0.01%	332
2022 Q4	$1.41M	Buy	983,285 +12,275	+1%	+$23.9K	0.01%	363
2022 Q3	$2.17M	Buy	971,010 +13,525	+1%	+$32.7K	0.02%	326
2022 Q2	$1.98M	Buy	957,485 +6,250	+0.7%	+$15.5K	0.01%	351
2022 Q1	$2.76M	Buy	951,235 +4,950	+0.5%	+$15.9K	0.02%	337
2021 Q4	$3.04M	Buy	946,285 +4,525	+0.5%	+$15.4K	0.02%	319
2021 Q3	$3.33M	Sell	941,760 -4,425	-0.5%	-$14.8K	0.02%	288
2021 Q2	$3M	Buy	+946,185	New	+$2.98M	0.02%	305
2017 Q1	–	Sell	-9,300	Closed	-$65K	–	761
2016 Q4	$65K	Hold	9,300	–	–	﹤0.01%	573
2016 Q3	$47K	Hold	9,300	–	–	﹤0.01%	608
2016 Q2	$56K	Hold	9,300	–	–	﹤0.01%	559
2016 Q1	$42K	Buy	+9,300	New	+$41.4K	﹤0.01%	578

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fuller & Thaler Asset Management's ENZ Position: Q3 2023 in Review

Fuller & Thaler Asset Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2023, closing a stake of 985,660 shares — an estimated $1.81M sold.

Fuller & Thaler Asset Management first reported a position in ENZ in Q1 2016 and held it in 13 quarters. The position peaked at $3.33M in Q3 2021. 39 funds tracked by Wall St. Rank hold ENZ as of Q3 2023.

Fuller & Thaler Asset Management reported no remaining Enzo Biochem, Inc. position as of Q3 2023 after selling out during the quarter.
Fuller & Thaler Asset Management sold 985,660 Enzo Biochem, Inc. shares in Q3 2023, an estimated $1.81M.
Fuller & Thaler Asset Management first reported a position in Enzo Biochem, Inc. in Q1 2016 and held it in 13 quarters.
Fuller & Thaler Asset Management's Enzo Biochem, Inc. position peaked at $3.33M in Q3 2021.
39 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2023.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.